Related Experiment Video
Updated: Dec 27, 2025
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Engineering of Live Chimeric Vaccines against Human Metapneumovirus
Daniela Ogonczyk Makowska1, Marie-Ève Hamelin1, Guy Boivin1
1Centre de Recherche en Infectiologie of the Centre Hospitalier Universitaire de Québec and Université Laval, Québec, QC G1V 4G2, Canada.
Abstract:
Human metapneumovirus (HMPV) is an important human pathogen that, along with respiratory syncytial virus (RSV), is a major cause of respiratory tract infections in young infants. Development of an effective vaccine against Pneumoviruses has proven to be particularly difficult; despite over 50 years of research in this field, no vaccine against HMPV or RSV is currently available. Recombinant chimeric viruses expressing antigens of other viruses can be generated by reverse genetics and used for simultaneous immunization against more than one pathogen. This approach can result in the development of promising vaccine candidates against HMPV, and several studies have indeed validated viral vectors expressing HMPV antigens. In this review, we summarize current efforts in generating recombinant chimeric vaccines against HMPV, and we discuss their potential optimization based on the correspondence with RSV studies.
Insights
Developing effective vaccines against human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) remains challenging. Recombinant chimeric viruses offer a promising strategy for simultaneous immunization against these important respiratory pathogens.
Area of Science:
- Virology
- Vaccinology
- Infectious Diseases
Background:
- Human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) are significant causes of infant respiratory infections.
- Despite decades of research, no licensed vaccines currently exist for HMPV or RSV.
Purpose of the Study:
- To review current advancements in developing recombinant chimeric vaccines against HMPV.
- To explore optimization strategies for HMPV vaccines by drawing parallels with RSV vaccine research.
Main Methods:
- Utilizing reverse genetics to create recombinant chimeric viruses expressing HMPV antigens.
- Analyzing existing studies on viral vectors for HMPV vaccine development.
- Comparing HMPV vaccine approaches with successful or unsuccessful RSV vaccine strategies.
Main Results:
- Several studies have demonstrated the potential of viral vectors expressing HMPV antigens as vaccine candidates.
- Recombinant chimeric viruses show promise for multi-pathogen immunization.
Conclusions:
- Recombinant chimeric virus technology represents a viable avenue for developing novel HMPV vaccines.
- Insights from RSV vaccine research can inform and optimize the development of HMPV vaccines.
